| Literature DB >> 29915563 |
Aneta Monika Gawlik1, Elzbieta Berdej-Szczot1, Dorota Blat2, Renata Klekotka2, Tomasz Gawlik3, Ewa Blaszczyk1, Magdalena Hankus1, Ewa Malecka-Tendera1.
Abstract
OBJECTIVE: The risk of autoimmune diseases (AD) in patients with Turner Syndrome (TS) is twice higher than in the general female population and four times higher than in the male population. The causes of the increased incidence of AD in TS are still under discussion. We hypothesized the presence of a specific humoral, cellular, and regulatory T cell (Treg) immunity profile which predisposes to AD, disorders of immunity, and disorders of immune regulation.Entities:
Keywords: T regulatory cells; Turner syndrome; autoimmunity; lymphocytes subpopulation
Year: 2018 PMID: 29915563 PMCID: PMC5994731 DOI: 10.3389/fendo.2018.00307
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Clinical parameters—girls with TS vs. healthy controls (mean ± SD).
| TS ( | CG ( | ||
|---|---|---|---|
| Age (years) | 11.9 ± 4.1 | 12.5 ± 4.0 | NS |
| Weight (kg) | 36.7 ± 14.8 | 45.2 ± 19.3 | NS |
| Height (cm) | 134.8 ± 20.0 | 146.3 ± 21.3 | NS |
| hSDS | −2.16 ± 0.95 | −0.41 ± 1.5 | <0.0001 |
| BMI | 19.2 ± 3.3 | 19.7 ± 4.6 | NS |
TS, Turner syndrome; CG, control group; n, number of patients; BMI, body mass index; hSDS, height standard deviation score; NS, not significant.
Laboratory markers of humoral and cellular immunity, and anti-inflammatory cytokines in girls with TS vs. healthy controls (mean ± SD).
| TS ( | CG ( | ||
|---|---|---|---|
| IgA (g/l) | 1.08 ± 0.39 | 1.15 ± 0.42 | NS |
| IgM (g/l) | 0.84 ± 0.30 | 1.01 ± 0.42 | NS |
| IgG (g/l) | 9.14 ± 2.10 | 11.15 ± 3.29 | 0.019 |
| TGF-β (pg/ml) | 260.2 ± 121.9 | 195.2 ± 113.7 | NS |
| IL-10 (pg/ml) | 7.38 ± 2.30 | 19.23 ± 38.39 | NS |
| CD3 (%) | 66.9 ± 7.3 | 68.2 ± 6.0 | NS |
| CD3 (cells/μl) | 1369.5 ± 504.8 | 1387.8 ± 531.4 | NS |
| CD4 (%) | 32.6 ± 5.5 | 40.4 ± 5.8 | NS |
| CD4 (cells/μl) | 656.3 ± 227.3 | 817.3 ± 350.1 | <0.001 |
| CD8 (%) | 28.6 ± 6.4 | 24.3 ± 5.4 | NS |
| CD8 (cells/μl) | 597.6 ± 272.6 | 494.8 ± 188.3 | NS |
| CD19 (%) | 16.4 ± 4.4 | 15.7 ± 4.9 | NS |
| CD19 (cells/μl) | 326.0 ± 108.9 | 329.4 ± 189.7 | NS |
| NK (%) | 14.3 ± 6.6 | 13.9 ± 6.5 | NS |
| NK (cells/μl) | 290.9 ± 171.2 | 263.8 ± 132.7 | NS |
| Treg (%) | 2.76 ± 1.56 | 2.37 ± 1.18 | NS |
TS, Turner syndrome; CG, control group; .
Laboratory markers of humoral and cellular immunity, and anti-inflammatory cytokines in girls with TS and the iXq karyotype vs. girls with TS non-iXq and vs. healthy controls (mean ± SD).
| TS iXq ( | TS non-iXq ( | CG ( | ||
|---|---|---|---|---|
| IgA (g/l) | 0.92 ± 0.43 | 1.11 ± 0.37 | 1.15 ± 0.42 | NS |
| IgM (g/l) | 0.87 ± 0.32 | 0.83 ± 0.31 | 1.01 ± 0.42 | NS |
| IgG (g/l) | 9.27 ± 3.07 | 9.11 ± 1.88 | 11.15 ± 3.29 | NS |
| TGF-β (pg/ml) | 209.8 ± 93.6 | 271.9 ± 126.0 | 195.2 ± 113.7 | NS |
| IL-10 (pg/ml) | 7.70 ± 2.09 | 7.30 ± 2.38 | 19.23 ± 38.39 | NS |
| CD3 (%) | 67.2 ± 8.1 | 66.8 ± 7.2 | 68.2 ± 6.0 | NS |
| CD3 (cells/μl) | 1374.3 ± 613.6 | 1368.2 ± 488.6 | 1387.8 ± 531.4 | NS |
| CD4 (%) | 30.8 ± 5.8 | 33.1 ± 5.5 | 40.4 ± 5.8 | NS |
| CD4 (cells/μl) | 625.7 ± 287.6 | 664.3 ± 216.0 | 817.3 ± 350.1 | 0.001 |
| CD8 (%) | 30.2 ± 6.5 | 28.2 ± 6.4 | 24.3 ± 5.4 | NS |
| CD8 (cells/μl) | 620.0 ± 294.1 | 591.8 ± 273.4 | 494.8 ± 188.3 | NS |
| CD19 (%) | 14.2 ± 2.0 | 16.9 ± 4.7 | 15.7 ± 4.9 | NS |
| CD19 (cells/μl) | 279.3 ± 102.0 | 338.1 ± 109.4 | 329.4 ± 189.7 | NS |
| NK (%) | 16.2 ± 7.3 | 13.8 ± 6.5 | 13.9 ± 6.5 | NS |
| NK (cells/μl) | 295.2 ± 112.8 | 289.7 ± 185.5 | 263.8 ± 132.7 | NS |
| Treg (%) | 1.84 ± 0.40 | 2.99 ± 1.66 | 2.37 ± 1.18 | NS |
TS, Turner syndrome; iXq, isochromosome Xq; CG, control group; .